On May 11, 2025, the 2025 Forbes China Top 50 Artificial Intelligence Technology Companies list was officially released. Landing Med earned a coveted position on the list, standing out as the only company solely focused on AI-powered cancer diagnostics. This recognition places Landing Med among the top tier of AI technology enterprises in China and signals authoritative international recognition of its pioneering work in applying artificial intelligence to healthcare. It also underscores China's growing leadership in the global AI healthcare landscape.
As a national high-tech enterprise, Landing Med has been at the forefront of integrating artificial intelligence with cloud-based pathological diagnostics. It pioneered the world's first large-scale application of AI technology in cancer cell pathology diagnosis, utilizing advanced tools like the all-in-one portable digital pathology slide scanner. Leveraging deep learning on millions of pathological images, its proprietary cervical cancer AI screening technology has achieved significant breakthroughs in both accuracy and speed. Compared to traditional methods, its AI models greatly enhance detection efficiency while reducing error rates—reaching world-leading performance metrics.
Through an innovative model that combines AI foundation models + digital cloud platforms + robotics, Landing Med has built a closed-loop solution encompassing sample collection, intelligent diagnosis, and health management. This model enabled comprehensive cervical cancer screening coverage for women across both urban and rural areas of Hubei Province, an achievement that the National Health Commission highlighted in its press briefing as the "Hubei Model". Landing Med's services now span over 2,000 medical institutions in China and have expanded into more than 10 countries across Southeast Asia and the Middle East. The company has also established several AI-based cancer screening laboratories, leveraging cutting-edge equipment such as high throughput cytology slide scanner and ensuring the availability of quality cytology consumables, delivering efficient, accessible diagnostic services to millions of patients annually.
In this year's Forbes ranking, Wuhan ranked fourth nationally with nine companies selected—following Shanghai, Beijing, and Shenzhen. Among them, eight enterprises hailed from Optics Valley, Wuhan's AI innovation hub, showcasing a full-spectrum industry chain from chip performance to vertical AI applications. Landing Med stands out as a flagship of this ecosystem, with its technological breakthroughs closely tied to the coordinated development of Optics Valley's AI industry cluster.
Recently, Dr. Junya Fukuoka, President of the Asian Society of Digital Pathology (ASDP) and Chair of the Digital Pathology Association (DPA) in the U.S., praised Landing Med during his visit, stating: "China is likely to lead the world in AI healthcare". His words reflect growing international recognition of Landing Med's influence in the professional domain and underscore how China's AI medical technologies are evolving from followers to global leaders.
Forbes China, one of the world's most influential business media brands, assessed candidates for the 2025 Top 50 AI Tech Companies based on six dimensions: technological innovation, market performance, social value, industry influence, business model, and growth potential. As transformative technologies like DeepSeek emerge, China's AI industry is rapidly reshaping the global innovation landscape. Landing Med's inclusion not only affirms its leadership in AI-powered healthcare, but also highlights Wuhan's strength as a national AI innovation pilot zone.
Looking ahead, Landing Med will continue to deepen the integration of AI and medicine, using early cancer screening as a strategic entry point. It aims to expand the application of AI in precision medicine and health management, contributing to the development of China's AI ecosystem and injecting scientific momentum into global health and wellness efforts.
fr 
es 
CN
